NO20054700L - Anvendelse av et fibrat og orlistat for behandling av fedme - Google Patents

Anvendelse av et fibrat og orlistat for behandling av fedme

Info

Publication number
NO20054700L
NO20054700L NO20054700A NO20054700A NO20054700L NO 20054700 L NO20054700 L NO 20054700L NO 20054700 A NO20054700 A NO 20054700A NO 20054700 A NO20054700 A NO 20054700A NO 20054700 L NO20054700 L NO 20054700L
Authority
NO
Norway
Prior art keywords
fibrate
orlistat
obesity
treatment
relates
Prior art date
Application number
NO20054700A
Other languages
English (en)
Norwegian (no)
Inventor
Alan Dunlap Edgar
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of NO20054700L publication Critical patent/NO20054700L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
NO20054700A 2003-03-13 2005-10-12 Anvendelse av et fibrat og orlistat for behandling av fedme NO20054700L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290625A EP1457206A1 (en) 2003-03-13 2003-03-13 Combined use of a fibrate and orlistat for the treatment of obesity
PCT/EP2004/004010 WO2004080450A2 (en) 2003-03-13 2004-03-12 Combined use of a fibrate and orlistat for the treatment of obesity

Publications (1)

Publication Number Publication Date
NO20054700L true NO20054700L (no) 2005-10-12

Family

ID=32749013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054700A NO20054700L (no) 2003-03-13 2005-10-12 Anvendelse av et fibrat og orlistat for behandling av fedme

Country Status (19)

Country Link
US (1) US20070078179A1 (zh)
EP (2) EP1457206A1 (zh)
JP (1) JP4928256B2 (zh)
CN (1) CN100562313C (zh)
AT (1) ATE384520T1 (zh)
AU (1) AU2004218938B2 (zh)
BR (1) BRPI0408322A (zh)
CA (1) CA2518205C (zh)
DE (1) DE602004011486T2 (zh)
DK (1) DK1601352T3 (zh)
EA (1) EA009127B1 (zh)
ES (1) ES2300750T3 (zh)
HK (1) HK1083767A1 (zh)
IL (1) IL170519A (zh)
MX (1) MXPA05009718A (zh)
NO (1) NO20054700L (zh)
PT (1) PT1601352E (zh)
WO (1) WO2004080450A2 (zh)
ZA (1) ZA200507227B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP2625968A1 (en) * 2007-09-12 2013-08-14 Københavns Universitet Composition and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2011130302A2 (en) 2010-04-12 2011-10-20 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
CA2895827A1 (en) * 2012-12-21 2014-06-26 Merck Patent Gmbh Magnesium hydroxide carbonate as excipient in pharmaceutical preparations having improved release of active ingredient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
WO2001060807A1 (en) * 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides

Also Published As

Publication number Publication date
US20070078179A1 (en) 2007-04-05
EA009127B1 (ru) 2007-10-26
CN100562313C (zh) 2009-11-25
IL170519A0 (en) 2006-10-05
ATE384520T1 (de) 2008-02-15
AU2004218938B2 (en) 2009-04-09
CA2518205A1 (en) 2004-09-23
BRPI0408322A (pt) 2006-03-14
WO2004080450A2 (en) 2004-09-23
CA2518205C (en) 2012-05-08
CN1826108A (zh) 2006-08-30
PT1601352E (pt) 2008-04-07
MXPA05009718A (es) 2005-10-18
DK1601352T3 (da) 2008-05-13
ES2300750T3 (es) 2008-06-16
WO2004080450A3 (en) 2005-02-24
EP1601352A2 (en) 2005-12-07
HK1083767A1 (en) 2006-07-14
AU2004218938A1 (en) 2004-09-23
IL170519A (en) 2010-12-30
DE602004011486D1 (de) 2008-03-13
DE602004011486T2 (de) 2009-01-15
JP2006520365A (ja) 2006-09-07
EP1601352B1 (en) 2008-01-23
EP1457206A1 (en) 2004-09-15
EA200501259A1 (ru) 2006-02-24
JP4928256B2 (ja) 2012-05-09
ZA200507227B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
DE60231295D1 (de) R und ppar modulatoren
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DE60330889D1 (de) Botulinum toxin zur behandlung von magengeschwür und gastroösophagealen reflux
PL374865A1 (en) Treatment of tnf alpha related disorders
DK1814590T4 (da) Behandling af obesitet og beslægtede sygdomme.
NO20034056D0 (no) Proliferative sykdommer
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
ATE369136T1 (de) Therapeutische behandlung
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
DE60239864D1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
FIU20020498U0 (fi) Vedenkäsittelylaitteisto
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
NO20050526L (no) Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling
ATE401321T1 (de) Beta-lactame zur behandlung von erkrankungen des zns
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
DE60115831D1 (de) Gugulipid zur Behandlung von kognitiven Störungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application